The association between Annexin A2 and epithelial cell adhesion molecule in breast cancer cells

Saad Misfer Al-Qahtani1,2 | Salah Eldin Gadalla1 | Min Guo1 | Christer Ericsson3 | Daniel Hägerstrand1 | Monica Nistér1

1Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
2Department of Pathology, College of Medicine and Najran University Hospital, Najran University, Najran, Saudi Arabia
3iCellate Medical AB, Stockholm, Sweden

Correspondence
Monica Nistér, Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J5:30, Visionsgatan 4, Stockholm, Solna SE-171 64, Sweden.
Email: monica.nister@ki.se

Funding information
Cancer Society in Stockholm, Karolinska Institutet and the Stockholm County Council; The Swedish Cancer Society; The Swedish Research Council

Abstract
Background: The epithelial cell adhesion molecule (EpCAM) is a type I transmembrane and glycosylated protein, which is overexpressed in many neoplasms. However, EpCAM has no known ligand partners and the mechanisms by which it functions are not fully understood.

Aim: This study was performed to discover novel partners of EpCAM, which may provide a better understanding of its functions.

Methods: The membrane fraction of the ERα+ noninvasive breast cancer cell line ZR-75-1 and MCF-7 was extracted and followed by co-immunoprecipitation of EpCAM using C-10, a mouse monoclonal antibody raised against amino acids 24–93 of the EpCAM molecule. As a negative control, MDA-MB-231 and Hs578T were used since they express a negligible amount of EpCAM and are known as EpCAM/C0/low ERα+/low invasive and tumorigenic breast cancer cell lines.

Results: Annexin A2 (ANXA2) was found to be selectively and differentially co-immunoprecipitated with EpCAM in the ERα+ breast cancer cells MCF-7 and ZR-75-1. ANXA2 is a multifunctional protein and known to act as a co-receptor for tissue plasminogen activator (tPA) on the surface of endothelial and cancer cells, thereby affecting fibrinolytic activity and neoangiogenesis as well as invasive and metastatic properties. In this study, the association between EpCAM and ANXA2 was found to affect the activity of tPA.

Conclusion: This study concludes that ANXA2 co-localizes with EpCAM at the plasma membrane, and the co-localization may have functional implications. Data suggest that EpCAM supports ANXA2 to function as a co-receptor for the tPA, and that EpCAM has a regulatory function on the expression and subcellular localization of ANXA2.

KEYWORDS
ANXA2, breast cancer, EpCAM, molecular pathology, tPA

1 | INTRODUCTION

The epithelial cell adhesion molecule (EpCAM) is a type I transmembrane and glycosylated protein which is overexpressed in many
neoplasms including high grade glial tumors, breast cancer, and colorectal cancer. However, there are complicated roles for EpCAM in the different cancers which may be attributed to the fact that the binding partners of EpCAM and the mechanisms by which it signals in and out of the cell are not fully known. Therefore, EpCAM co-immunoprecipitation was performed and followed by mass spectrometry and peptide sequencing to search for new potential binding partners of EpCAM. The endoplasmic reticulum aminopeptidase 2 (ERAP2) has been identified by our group as an EpCAM-associated protein, and here we continue this effort and present another novel finding that Annexin A2 (ANXA2) is a potential interacting partner of EpCAM in the EpCAM$^+$ ERα$^+$ breast cancer cells.

Annexins are a family of proteins with more than 22 members that have been isolated from a variety of cells and tissues and are involved in diverse physiological activities. Annexins consist of a variable amino terminal “tail” domain followed by four or eight conserved repeats. Annexins in general bind to biological membranes and anionic phospholipids in a Ca$^{2+}$ dependent manner through these conserved repeats. ANXA2 belongs to this family of membrane binding proteins, and it controls apical plasma membrane and lumen formation. The protein may cross-link plasma membrane phospholipids with actin and the cytoskeleton and be involved in exocytosis, membrane and vesicular trafficking.

ANXA2 was discovered by many investigators independently and given a variety of names (p34, p36, p39, calpactin I heavy chain, protein I, chromobindin-8, lipocortin II and placental anti-coagulant protein IV). ANXA2 contains two light chains of S100A10/p11 and two heavy chains of S100A9/p23. A heterotetramer of ANXA2 contains two light chains of S100A10/p11 and two heavy chains of AnxA2/p36 and localizes to the cell surface.

The tetramer exists in the sub-plasma lemmal cytoskeletal network in different cell types. As a monomer, ANXA2 is found in both the cytosol and nucleus, but predominantly in the cytosol. The function of the ANXA2 monomer in the nucleus was suggested by its purification as part of a primer recognition protein complex that enhances DNA polymerase α activity in vitro. Through S100A10, ANXA2 has been reported to function as a co-receptor for tissue plasminogen activator (tPA) at the cell surface. In a previous report, it was shown that depletion of ANXA2 in telomerase immortalized microvascular endothelial cells led to the loss of plasminogen binding and plasmin generation similar to when S100A10 was depleted. Furthermore, analysis of AnnexinA2-null mice showed that tPA-dependent plasmin generation at the endothelial cell surface is markedly deficient in the absence of ANXA2. The phenotype of these mice showed that ANXA2 is a regulator of cell surface plasmin generation and that impaired endothelial cell fibrinolytic activity constitutes a barrier to effective neoangiogenesis.

The tPA is one of the proteases that convert the plasminogen to the active plasmin, and plasmin is involved in the degradation of the extracellular matrix. The degradation of the extracellular matrix is a reported mechanism for progression of cancer, invasion and metastasis.

This study presents a novel finding that ANXA2 is an interacting partner of EpCAM in the EpCAM$^+$ ERα$^+$ breast cancer cells, and co-localizes with EpCAM at the plasma membrane of EpCAM$^+$ ERα$^+$ breast cancer cells. This co-localization may have a functional background since EpCAM appeared to support ANXA2 to function as a co-receptor for the tPA, and EpCAM seemed to have a regulatory function on the expression of ANXA2.

## 2 | MATERIAL AND METHODS

### 2.1 | Cell lines

MCF-7, ZR-75-1 and MC2 are ERα$^+/+$ and EpCAM$^+/+$ breast cancer cell lines while MDA-MB-231 and Hs578T are ERα$^-$/low and EpCAM$^-$/low breast cancer cell lines. All cell lines were grown in DMEM with 10% fetal calf serum, 1% l-glutamine, 1% sodium pyruvate (all from Gibco) and 1% penicillin/streptomycin (SIGMA). All of the breast cancer cell lines were provided by Professor Jonas Bergh’s laboratory at the Department of oncology-pathology, Karolinska Institutet, Stockholm, Sweden except MC2 which was provided by Professor V. Craig Jordan, Fox Chase Cancer Center’s Division of Medical Science, USA. All the cell lines were used in two previous publications from our group. In those studies we could confirm their expected expression patterns of several breast cancer proteins as well as their phenotypes.

### 2.2 | Subcellular fractionation and EpCAM co-immunoprecipitation followed by gel staining, band picking and mass spectrometry

#### 2.2.1 | Subcellular fractionation

MCF-7, ZR-75-1, MDA-MB-231 and Hs578T cells were grown on 6-well plates up to 70%-80% confluence, and each cell line in duplicate. Then the cells were washed three times on ice with cold PBS and scraped off, cells were then spun down for 5 min at 700 G, 4 °C. Cell pellets were re-suspended in homogenization buffer (250 mM sucrose, 10 mM Tris–HCl buffer, pH 7.4). Homogenization was performed by drawing and releasing the suspended cells many times using 22 G needle and 10 cc syringe and the material was then spun down for 15 min at 1500 G, 4 °C. The supernatant constitutes cytosolic proteins and membrane proteins, and it was then transferred to Sorval™ and centrifuged 10 600 rcf for 1 h at 4 °C. The supernatant represents cytosolic fraction while the pellet is membrane fraction.

#### 2.2.2 | Immunoprecipitation

The membrane fraction of the MCF-7, ZR-75-1, MDA-MB-231 and Hs578T cells was solubilized in ice-cold RIPA buffer 1:10 volume (RIPA buffer: 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0, 1% Non-Idet P-40/NP-40), and the suspension was centrifuged at 16 000 rcf for 15 min at 4 °C. To clear any
unbound immune complexes, the supernatant was incubated with protein G agarose beads at 4°C for 2 h (Immunoprecipitation starter pack, GE Healthcare), beads were spun down by centrifuging for 3 min at 3000 rcf and the supernatant was incubated with mouse monoclonal anti-human EpCAM (C-10, Santa Cruz) at a dilution of 2 μg per 100-500 μg of total protein (in 1 mL of cell lysate) overnight at 4°C. Immune complexes were captured with protein G agarose beads for 2 h at 4°C, eluted with 50 μL 2× SDS sample buffer, shaken at 95°C for 10 min and centrifuged. The resulting supernatant represents EpCAM with possible co-immunoprecipitated proteins.

2.2.3 | SDS-PAGE

Immunoprecipitated (IP) protein samples were run in 10% SDS-PAGE, and for all cell lines analyzed the IP lane was compared to the total cell extract (input). Gel was stained overnight by mild shaking in Colloidal Blue Staining Kit from Invitrogen, it was destained with deionized water over 8–12 h, where after differentially expressed bands were identified, gel slices were cut out and sealed in a clean plastic bag and sent for ESI-MALDI MS–MS and peptide mass fingerprinting (Proteomics Resource Center, Department of Medical Biochemistry and Microbiology, Biomedical Center, Uppsala University, Sweden). Finally, querying NCBI Protein, OMIM, Swissprot and ExPASy identified proteins.

2.3 | Validation of protein–protein association by reciprocal Co-IP and Western blotting in ZR-75-1 cells

Total cell extracts were prepared from the cell cultures after washing with cold PBS three times, and solubilization in RIPA buffer and co-immunoprecipitation was performed as described above, except that immunoprecipitates were captured on magnetic beads. The immunoprecipitates were dissolved in 2× SDS. Total protein concentration was measured using the Bio-Rad RCDC assay and 50 μg total protein per lane was loaded on to 10% SDS PAGE gel and separated. The separated proteins were transferred overnight to nitrocellulose membrane (Schleicher & Schuell Protran BA 83) using wet Western blot transfer. The membrane was washed with TBS-T (25 mM Tris–HCl, pH 8.0, 125 mM NaCl, 0.1% Tween 20) and then blocked for 1 h with 10% membrane blocking agent in PBS (Amersham). Incubation with the primary antibody (the mouse monoclonal C-10 against EpCAM alternatively the H-50 rabbit polyclonal antibody against ANXA2 [both from Santa Cruz]) was overnight at 1:2000 dilution at 4°C. The membrane was washed and subsequently incubated with the appropriate secondary antibody for 1 h at room temperature. After washing with TBS-T, a mixture of Amersham ECL Western blotting detection reagent 1 and 2 was poured onto the membrane and incubated for 1 min. Luminescence was imaged by Fuji Film LAS-1000 and images analyzed using LAS-1000 and Image Gauge software. This experiment was conducted twice and independently.

2.4 | Subcellular co-localization of ANXA2 and EpCAM by double immunofluorescence staining and confocal microscopy

MCF-7, ZR-75-1, MC2, MDA-MB-231 and Hs578T cells were cultured on coverslips in six-well plates. Each cell line was seeded in four wells (n = 4), incubated as described above and this experiment was performed twice and independently. After reaching 70%–80% confluence, the cell cultures were washed gently twice in PBS and fixed in 96% ethanol for 15 min at room temperature. After washing twice in PBS, cells were permeabilized with 0.5% Triton X-100 in PBS for 15 min followed by blocking in 10% BSA in PBS for 1 h at 4°C, then incubated overnight in a humid chamber at 4°C with the mouse monoclonal C-10 against EpCAM and the H-50 rabbit polyclonal antibody against ANXA2 (both from Santa Cruz). Second day the slips were washed three times in PBS for 40 min and incubated with the corresponding conjugated secondary antibodies, DyLight 594-conjugated anti-mouse IgG (red) and DyLight 488-conjugated anti-rabbit IgG (green) (Both from Vector Labs) in 1:1000 dilution for 1 h at 4°C and then washed three times with PBS at room temperature. For visualizing the nuclei, a drop of Vectashield mounting media with DAPI (Vector Labs) was added. Then, TCS SP5 confocal microscopy system (Leica) was used to visualize and examine the cells.

2.5 | Transfection of siRNA constructs

MCF-7, ZR-75-1, MDA-MB-231 and Hs578T cells were cultured in six-well plates. Silencer™ Select Pre-Designed siRNA (Thermo Scientific) was used to silence both ANXA2 (Catalog#: 4390826, siRNA ID: s1383) and EpCAM (Catalog #: 4392422, siRNA ID: s8370). As a negative control, Silencer™ Select Negative Control (Thermo Scientific, Catalog #4390844) was used. This was in the presence of another control group of cells that was not treated at all, and each group of the controls and siRNA-treated group was grown in four wells (n = 4). The transfection was carried out using Lipofectamine-2000 reagents (Invitrogen) and OPTI-MEM serum free media (GIBCO). After 24 h of incubation at 37°C, the transfection was repeated, and the cells were harvested after another 48 h for further studies including assessment of relative gene expression and protein levels as described below.

2.6 | Relative gene expression: RNA extraction, cDNA synthesis, and qPCR using SYBR Green

2.6.1 | RNA extraction and cDNA synthesis

After the transfection, total RNA was extracted using the RNeasy mini kit from Qiagen, and the amount of RNA was assessed by NanoDrop (Thermo Scientific, USA). The cDNA from each sample was then synthesized using 1 μg of RNA added to previously mixed 1 μL of Oligo (dT) 12–18 bp primers (Invitrogen) and 1 μL of dNTP Mix (Invitrogen), incubated for 5 min at 65°C and reaction stopped by incubation on
ice for 1 min. After that the mixture was added to a premix that was made of 4 μL of 5× first single strand buffer, 1 μL of RNaseOut Recombinant, 1 μL of 0.1 M DTT, and 1 μL of Superscript III RT (all from Invitrogen). The generated cDNA was diluted and kept at –20°C.

2.6.2 | qPCR using SYBR Green

The qPCR was done using the 2XSYBR Green Master Mix Kit (Applied Biosystem), and all the primers were obtained from Invitrogen (Table 1). The relative expression was calculated by the \( \Delta \Delta Ct \) method after calculating the average since each sample in each group was assessed in triplicate \( (n = 4) \). The normalized Ct values \( (\Delta Ct) \) were calculated by subtracting the Ct values of the target genes from that of GAPDH. The \( \Delta \Delta Ct \) values were then calculated by subtracting the normalized value for the target gene from that of the control, and the formula \( 2^{-\Delta \Delta Ct} \) was used to calculate the relative expression of the target gene in comparison to the control which was given the value 1.

2.7 | Western blot

After the transfection of siRNA and control, proteins were extracted using radioimmunoprecipitation assay (RIPA) buffer, and the amount of the protein quantified according to a standard assay protocol (DC protein assay, Bio-Rad, USA). About 50 μg of each sample prepared with SDS-loading buffer and proteins were separated on NUPAGETM 4%–12% Bis–Tris protein gels (Invitrogen). Each sample from each group \( (n = 4) \) were run in duplicates. Then, proteins were transferred to PVDF membranes using Trans-Blot Turbo transfer system (Bio-Rad). Membranes were blocked with 5% non-fat milk in PBS and incubated with the primary antibodies (Table 2) overnight. The next day, after washing several times with TBS-T, membranes were incubated with the appropriate peroxidase-conjugated secondary antibody (GE Healthcare) for 1h. Finally, membranes were immersed with the Pierce ECL Western Blotting Substrate (Thermo Scientific), and luminescence was imaged by Fuji Film Las-1000 and images analyzed using ImageJ.

2.8 | tPA chromogenic activity assay

Using tPA activity assay kit (Colorimetric, Human ab108905, Abcam), the amount of unbound tPA was assessed according to the manufacturer’s protocol. MCF-7 and ZR-75-1 were treated with siRNA-cont, siRNA-EpCAM, siRNA-ANXA2, or both siRNA-EpCAM and siRNA-ANXA2; in presence of control groups that were not treated at all. MDA-MB-231 and Hs578T were transfected by either siRNA-cont or siRNA-ANXA2, in presence of control groups that were not treated at all as well. After 72 h of siRNA transfection, the cell culture supernatants from each well were collected and centrifuged to remove debris. Using the microplate provided by the manufacturer, 80 μL of the Assay Mix (60 μL diluent, 10 μL plasminogen, 10 μL plasmin substrate) added to 20 μL of each sample (cell culture supernatant) or 20 μL of different concentrations of tPA standard \((16, 8, 4, 2, \text{ and } 0 \text{ IU/mL})\). Each group \( (n = 3) \) was assessed in triplicates except control groups and standards that were assessed in duplicates. Then, the absorbance at 405 nm at zero minutes was read, and the microplate was incubated in humidified incubator at 37°C. The absorbance at 405 nm was assessed periodically every 30 min for 2 h. In parallel, the cells were used to analyze protein levels, and the extraction of protein was performed directly after removing the supernatants. This experiment was performed twice and independently.

2.9 | Statistical analyses

All results were generated from at least two independent experiments. Data were analyzed using the Prism Graph Pad Software (CA, USA). All values are presented as mean ± SD. Significances were calculated using analysis of variance (ANOVA), followed by multiple comparisons. The values of \( p < .05 \) were considered significant whereas * indicates \( p \)-value <.05, **\( p \)-value <.01 and ***\( p \)-value <.001.

---

**TABLE 1** | The primers used during the assessment of the relative expression levels

| Primer | Sequence (5′-3′) | Amplicon size |
|--------|-----------------|--------------|
| F-ANXA2 | GAGCGGGATGCTTTGAACATT | 119 |
| R-ANXA2 | TAGGCGAAGGCCAATCTCGT | |
| F-EpCAM | AATCGTCAATGCCAGTGTACTT | 178 |
| R-EpCAM | TCTCATCGCAGTCAGGATCATAA | |
| F-GAPDH | GGAGCGAGATCCCTCAATT | 197 |
| R-GAPDH | GGCTGTTGTCATACTTCTCATG | |

**TABLE 2** | The antibodies were used during the study of protein levels

| Antibody | Source | Clone | Provider |
|----------|--------|-------|----------|
| Anti-EpCAM | Mouse monoclonal | C-10 | Santa Cruz |
| Anti-ANXA2 | Rabbit polyclonal | H-50 | Santa Cruz |
| Anti-GAPDH | Mouse monoclonal | | Santa Cruz |
| HRP-conjugated anti-mouse | Sheep | Secondary | GE healthcare |
| HRP-conjugated anti-rabbit | Donkey | Secondary | GE healthcare |
### TABLE 3: Summary of findings from mass spectrometry and peptide mass fingerprinting

| Name of the protein | Symbol | Score | Function |
|---------------------|--------|-------|----------|
| Actin B             | ACTB   | 93/64 | Non muscle cytoskeletal actins, highly conserved proteins, involved in cell motility |
| Keratin 18          | CK18   | 174/64| Intermediate filament that acts as structural cytoskeleton |
| Keratin 8           | CK8    | 123/64| Intermediate filament that acts as structural cytoskeleton |
| Keratin 9           | CK9    | 89/64 | Intermediate filament that acts as structural cytoskeleton |
| Keratin 1           | CK1    | 65/64 | Intermediate filament that acts as structural cytoskeleton |
| Keratin 19          | CK19   | 311/64| Intermediate filament that acts as structural cytoskeleton |
| Heat shock protein 70 9B | HSP70 9b | 108/64| Heat related protein that is involved in the folding and unfolding of other proteins |
| Heat shock protein 90 AA1 | HSP90 AA1 | 112/64| Involved in the folding and unfolding of other proteins |
| Heat shock protein 70 8 isoform 2 | HSP70 8 2 | 71/64| Involved in the folding and unfolding of other proteins |
| Myosin (non-muscle) | Myosin | 285/64| Cross links actin (motor function) |
| Vimentin            | VIM    | 296/64| Type III intermediate filament (IF) protein that is expressed in mesenchymal cells |
| heterogeneous nuclear ribonucleoprotein A2/B1 | hnRNP A2 | 152/64| RNA binding protein, influences pre-mRNA processing and other aspects of mRNA metabolism and transport in the nucleus |
| Fatty acid synthase  | FASN   | 174/66| A multi-enzyme, catalyzes fatty acid synthesis |
| Clathrin heavy chain I | CLTC | 126/66| A major protein component of coated vesicles, involved in the intracellular trafficking of receptors and endocytosis |
| ANXA2               | ANXA2  | 163/66| Membrane trafficking, anticoagulation through binding tPA, cell adhesion by binding tenasin C |
| ERAP2 (LRAP)        | ERAP2  | 73/66 | ERAP2 is an aminopeptidase set in the endoplasmic reticulum (ER), a single-pass type II membrane protein that plays a central role in peptide trimming. Major histocompatibility complex (MHC) class I molecules rely on aminopeptidases such as ERAP2 to trim precursors to antigenic peptides in ER. ERAP2 preferentially hydrolizes the basic residues Arg and Lys |
| Valyl-tRNA synthetase| VARS   | 81/66 | Catalyzes the aminocacylation of tRNA by their cognate amino acids (protein synthesis) |
| Eukaryotic translation elongation factor 2 | EEF2 | 198/66| GTP-binding translation elongation factor, involved in protein synthesis |
| Valosin-containing protein | VCP | 198/66| ATP-binding proteins involved in vesicle transport and fusion |
| Enolase 1 (alpha-enolase) | ENO1 | 107/66| A glycolytic enzyme |
| Aldolase A           | Aldolase A | 94/66| An enzyme that catalyzes a reverse aldol reaction: The substrate, fructose 1,6-bisphosphate (F-1,6-BP) is broken down into glyceraldehyde 3-phosphate and dihydroxyacetone phosphate (DHAP). This reaction is a part of glycolysis |
| Lactate dehydrogenase A | LDHA | 112/66| An enzyme that catalyzes the conversion of L-lactate and NAD+ to pyruvate and NADH in the final step of anaerobic glycolysis |
| Seryl-tRNA synthetase | SARS | 136/66| An enzyme that catalyzes the transfer of L-serine to tRNA |

Note: Data are based on EpCAM co-immunoprecipitates from the membrane fraction of ZR-75-1 cells. Information on protein function is from the NCBI-OMIM database.

### TABLE 4: Primary data from the mass spectrometry-based identification of ANXA2 in EpCAM co-immunoprecipitates

| Accession | Mass | Score | Description |
|-----------|------|-------|-------------|
| 1. gi 4757756 | 38 808 | 163 | Annexin A2 isoform 2 [Homo sapiens] |
| 2. gi 56966699 | 38 866 | 163 | Chain A, Annexin A2; Does It Induce |
| 3. gi 18645167 | 38 780 | 163 | Annexin A2 [Homo sapiens] |
| 4. gi 16306978 | 38 822 | 163 | Annexin A2 [Homo sapiens] |
| 5. gi 73909156 | 40 731 | 161 | Annexin A2 [Homo sapiens] |
3 | RESULTS

3.1 | Co-immunoprecipitation of ANXA2 with EpCAM in breast cancer cells

The gel used to separate the proteins after immunoprecipitation and from which slices were sent for the mass spectrometry is provided as a Figure S1 which was published as part of our coauthor’s doctoral thesis. Additionally, in the mass spectrometry analysis of ZR-75-1 cells, several proteins were found co-immunoprecipitated with EpCAM. Peptide finger printing was done, matched with NCBI protein database, Swissprot and ExPASy. Those proteins showing a statistically significant score are listed in Table 3. ANXA2 was identified with a score of 163/66 in the EpCAM+ ZR-75-1 cell line (Tables 3 and 4), while it was not picked up by EpCAM co-immunoprecipitation followed by mass spectrometry analysis in MDA-MB-231 cells in which EpCAM is known to be almost absent (not shown). To confirm this finding, we first identified ANXA2 as a 38 kDa protein present at similar levels in ERα+ and ERα− breast cancer cells (Figure 1(C)). Then EpCAM co-immunoprecipitation was repeated, and the precipitates were analyzed by Western blotting using ANXA2 antibodies. The reciprocal co-immunoprecipitation was performed using ANXA2 antibodies followed by Western blot analysis of EpCAM in the precipitates. This confirmed association between EpCAM and ANXA2 in ZR-75-1 cells (Figure 1(D),(E)).

3.2 | Co-localization of ANXA2 and EpCAM in breast cancer cells

Double immunofluorescence staining was performed to determine the subcellular localization of the two proteins. ANXA2 (green) displayed cytoplasmic as well as nucleolar staining patterns in all tested breast cancer cell lines, both in ERα+ and ERα− cells (Figure 2(A)).

FIGURE 1 (A) Schematic illustration of human EpCAM protein domain structure. It is formed of 314 amino acids, and there are three domains: extracellular (the largest), transmembrane and cytoplasmic domain. (B) Schematic illustration of human ANXA2 protein domain structure. It is formed of 339 amino acids. The domain for S100A10/p11 binding as well as known sites for regulatory tyrosine phosphorylation by pp60src and serine phosphorylation by PKC are all localized in the N-terminal domain as illustrated. (C) EpCAM and ANXA2 proteins in breast cancer cell lines. Western blot analysis of total cell lysates from breast cancer cells using EpCAM, ANXA2, and GAPDH antibodies. This experiment was repeated twice and independently. (D) and (E) Reciprocal co-immunoprecipitation of EpCAM and ANXA2 in total cell extracts from ZR-75-1 breast cancer cells. EpCAM co-immunoprecipitation followed by Western blotting using ANXA2 antibodies confirmed an association between the two proteins in the ERα+ breast cancer cell line ZR-75-1. Notice that EpCAM appears as a band around 40 kDa while ANXA2 is slightly smaller, with a band at 38 kDa. This study was performed twice and independently, and plain beads without antibodies were added to the extract as a negative control.
However, ANXA2 in ERα+ cells was clearly distributed at the plasma membrane more than in the cytoplasm and the nucleus in which it had a dot-like appearance; while in ERα− cells ANXA2 appeared diffusely in cytoplasm and nucleus (Figure 2A). EpCAM (red) showed membranous localization in MCF-7, ZR-75-1 and a subset of MC2 cells but was not detected in MDA-MB-231 and Hs578T cells. ANXA2 and EpCAM co-localized as a line or dots, mainly at the plasma membrane of the ERα+ cells (Figure 2A). Also, peripheral lamellae and membrane ruffles displayed ANXA2-EpCAM co-localization as illustrated in MCF-7 (Figure 2B), in addition to the

![Figure 2](image-url)

**Figure 2** The images are representative of each respective group (n = 4), and the experiment was conducted twice and independently. (A) Co-localization of ANXA2 and EpCAM by double immunofluorescence staining of breast cancer cells. The subcellular localization of EpCAM and ANXA2 is illustrated by double immunofluorescence staining. Note the absence of EpCAM in MDA-MB-231 and Hs578T cells and positive immunostaining in MCF-7 and ZR-75-1. In EpCAM positive cells the two proteins co-localize mainly in a membranous pattern and ANXA2 is additionally present in the cytoplasm and nucleoli of all the cell lines tested. (B) Special view to illustrate co-localization of EpCAM and ANXA2 in lamellae and membrane ruffles (yellow) at the cell periphery of MCF-7 cells. (C) Different subcellular localization of ANXA2 in EpCAM+ and EpCAM− MC2 cells. MC2 cells expressing a lesser amount of EpCAM (white arrows) have their ANXA2 mainly localized in the cytoplasm and in these cells the membranous co-localization in merged pictures is almost lacking. (D) A magnified panel to show MC2 cells that express a lesser amount or nothing of EpCAM (white arrows), compared to the MC2 that expresses EpCAM.
most distinct plasma membrane co-localization in places where cells were closely attached to each other. In MC2 cells, which are originally MDA-MB-231 cells engineered to express ERα, ANXA2-EpCAM co-localization was also seen more diffusely in lamellae, at the periphery of cells (Figure 2(C)). In the MC2 cultures where only a subset of cells expressed EpCAM, ANXA2 tended to be localized only in the cytoplasm of EpCAM− cells, while also at the cell periphery of EpCAM+ cells (Figure 2(D)).
Figure 3 Each group was assessed in triplicates (mRNA levels) or duplicates (protein levels) (n = 4). The values of p < 0.05 were considered significant whereas * indicates p-value < 0.05, **p-value < 0.01 and ***p-value < 0.001. (A) The mRNA levels of ANXA2 in MCF-7 and ZR-75-1: The control siRNA did not change the levels, compared to the control groups. However, siRNA-ANXA2 and/or siRNA-EpCAM led to a significant reduction in the mRNA levels of ANXA2. (B) The mRNA levels of EpCAM in MCF-7 and ZR-75-1: The control siRNA did not change the levels, compared to the control groups. In contrast, siRNA-ANXA2 and/or siRNA-EpCAM led to a significant reduction in the mRNA levels of EpCAM. (C) Immunoblotting shows protein levels of EpCAM, ANXA2, and GAPDH in MCF-7: control, control-siRNA, siRNA-ANXA2 group, siRNA-EpCAM, and double-siRNA targeted both ANXA2 and EpCAM. (D) Immunoblotting shows protein levels of EpCAM, ANXA2, and GAPDH in ZR-75-1: control, control-siRNA, siRNA-ANXA2 group, siRNA-EpCAM, and double-siRNA targeted both ANXA2 and EpCAM. (E) The protein levels of ANXA2 normalized to GAPDH in MCF-7 and ZR-75-1: In consistence with mRNA levels in panel A, the control siRNA did not change the levels, compared to the control groups. However, siRNA-ANXA2 and/or siRNA-EpCAM led to a significant reduction in the protein levels of ANXA2. (F) The protein levels of EpCAM normalized to GAPDH in MCF-7 and ZR-75-1: The control siRNA and siRNA ANXA2 did not change the levels of EpCAM, compared to the control group. Meanwhile, siRNA-EpCAM and the double-siRNA led to a significant reduction in the protein levels of EpCAM.
3.3 The mRNA, protein levels and co-localization of ANXA2 and EpCAM in breast cancer cells after silencing EpCAM and/or ANXA2

Using siRNA against ANXA2 (siRNA-ANXA2) (Figure 3(A)) and EpCAM (siRNA-EpCAM) (Figure 3(B)) in MCF7 and ZR-75-1 resulted in a significant reduction of their respective mRNA levels, compared to the control groups (Figure 3(A),(B)). In the ERα−/low and EpCAM−/low cells, the mRNA levels of ANXA2 were suppressed significantly upon siRNA treatment, in comparison to the control group treated with negative control siRNA (Figure S2(A)). Noteworthy, the significant reduction in the mRNA levels of ANXA2 due to siRNA-ANXA2 was accompanied by a significant reduction in ANXA2 due to siRNA-EpCAM (Figure 3(A)). Moreover, the significant suppression of the mRNA levels of EpCAM due to siRNA-EpCAM treatment was paralleled by significantly suppressed levels of EpCAM due to siRNA-ANXA2 (Figure 3(B)).

At protein levels, siRNA-ANXA2 resulted in a significant reduction of ANXA2 in all cells MCF-7, ZR-75-1 (Figure 3(C)–(F)), MDA-MB-231 and Hs578T (Figure S2(B),(C)). Also, siRNA-EpCAM reduced the protein levels of EpCAM significantly in MCF-7 and ZR-75-1 (Figure 3(C)–(F)). Consistent with the observed mRNA levels, the immunoblotting showed that both siRNA-EpCAM and siRNA-ANXA2 reduced the protein levels of ANXA2 significantly in MCF7 and ZR-75-1 (Figure 3(C)–(E)). However, the observed protein levels of EpCAM were not consistent with its mRNA levels; EpCAM protein levels were not affected by siRNA-ANXA2 (Figure 3(C),(D),(F)).

Double immunofluorescence staining was performed again to study the subcellular localization of the two proteins after silencing ANXA2 or EpCAM. In MCF-7 and ZR-75-1, siRNA-ANXA2 did not affect the localization of EpCAM to the cell membranes despite that the signals of EpCAM were weaker mainly in ZR-75-1, compared to the controls (Figure 4(A),(B)). Upon siRNA-EpCAM treatment of both MCF-7 and ZR-75-1, however, the localization and signal of ANXA2 was almost lost to a level comparable to when ANXA2 was targeted by siRNA-ANXA2 (Figure 4(A),(B)).

3.4 Effects of silencing EpCAM and/or ANXA2 on tPA

In the cell culture supernatants of MCF-7 and ZR-75-1, silencing of ANXA2 or EpCAM led to a significant increase in the concentration of unbound tPA in the cell culture supernatants, compared to the control (Figure 5(A),(B)). The concentration of unbound tPA in the cell culture supernatants increased and magnified upon silencing both ANXA2 and EpCAM in the double siRNA group. In the ERα−/low and EpCAM−/low cells, that are the MDA-MB-231 and Hs578T, the concentration of unbound tPA in the cell culture supernatants increased significantly due to siRNA-ANXA2 treatment (Figure 5(C)).

4 DISCUSSION

The binding partners of EpCAM and the mechanisms by which EpCAM signals in and out of cells have been extensively studied but are not fully known. Therefore, the current study used EpCAM...
co-immunoprecipitation followed by mass spectrometry and peptide fingerprinting to search for new potential binding partners of EpCAM. In the mass spectrometry analysis of ZR-75-1 EpCAM immunoprecipitates, a number of proteins were identified as co-precipitated with EpCAM, and those proteins showing a statistically significant score in the identification process are listed in Table 3. It was appreciated that several of those proteins are abundant cellular proteins and can be viewed as background. However, the list included cytoskeletal proteins characteristic of cultured epithelial cells, and other proteins that are involved in several biological functions such as ANXA2. Additionally, one of the identified proteins was fatty acid synthase (FASN), which was previously reported to associate with EpCAM.29

For confirmation of protein co-localization, we selected proteins that may contribute important novel functional mechanisms if a direct or indirect association with EpCAM can be confirmed. ERAP2 was identified by our group in a previous publication, and the latter association are presently unknown.

EpCAM protein, as our group reported previously, is formed of 314 amino acids, and there are three domains: extracellular (the largest), transmembrane and cytoplasmic domain (Figure 1(A)). The ANXA2 protein is formed of 339 amino acids, and the amino acid sequence is shown in the Table 5. In the N-terminal domain, the domain for S100-10A binding as well as known sites for regulatory tyrosine phosphorylation by pp60src and serine phosphorylation by PKC are all localized (Figure 1(B)). The assessment of the protein levels of ANXA2 and EpCAM relative to GAPDH showed that ANXA2 is expressed in all breast cancer cell lines whilst EpCAM is expressed only in the ERα+ cells ZR-75-1 and MCF-7 (Figure 1(C)). The latter observation is consistent with what has been reported previously.30

Double immunofluorescence stains on EpCAM and EpCAM showed that the two proteins co-localized mainly in a membranous pattern. Using siRNA-ANXA2, the signal intensity of EpCAM was weaker. However, by using siRNA-EpCAM treatment, the localization and signal of ANXA2 was almost lost to a level comparable to when ANXA2 was targeted by siRNA-ANXA2 (Figure 4(A),(B)). Regarding the latter observation, it was thought that losing the localization and signal of ANXA2 due to siRNA-EpCAM might be related to the secretion of ANXA2 to extracellular space or medium.31 However, the relative expression of ANXA2 at both mRNA (Figure 3(A)) and protein level (Figure 3(C),(D)) was significantly reduced due to siRNA-EpCAM. In addition to that, the si-RNA-ANXA2 treatment led to a significant reduction at mRNA level of EpCAM (Figure 3(B)). Despite the protein levels of EpCAM were not affected significantly (Figure 3(D),(F)) by siRNA-ANXA2, these results suggest that EpCAM has a regulatory function on the expression and localization of ANXA2 as well as that ANXA2 and EpCAM may be involved in regulating the expression of each other.

The current study also assessed the amount of unbound tPA in the supernatant of the cells after silencing ANXA2 and/or EpCAM. This is because ANXA2 has been reported to function as a coreceptor for tissue plasminogen activator (tPA) at the cell surface of endothelial and cancer cells, and the current study suggests the co-localization, dependence and interaction between ANXA2 and EpCAM at the cell surface. Our results showed that silencing of ANXA2 or EpCAM in the ERα+ cells led to a significant increase in the concentration of unbound tPA in the cell culture supernatants, control to the comparison (Figure 5(A),(B)). Moreover, the concentration of unbound tPA in the cell culture supernatants increased and magnified upon silencing of both ANXA2 and EpCAM as a double-siRNA treatment (Figure 5(A),(B)). These results indicated that ANXA2 may serve as a co-receptor for tPA in an EpCAM-dependent manner, since absence of the co-receptor ANXA2 or its partner EpCAM led to accumulation of tPA in the supernatant as unbound tPA, which in turn may be associated with low plasmin generation.33 During assessment

| Amino terminus | 10 | 20 | 24 | 26 | 30 | 40 | 50 | 60 |
|---------------|---|----|----|----|----|----|----|----|
| MSTVHEILCK    | LSLDGHSTP | PSAYGSVKAY | TNFDAERDAL | NIETAIKTG | VDEVTIVNL |                |    |    |
| TNRNA QRQD    | IAFAYQRTK  | KELASALKSA | LGHLETVL | GLLKTPAQYD | ASELKASMKG  |                |    |    |
| LGTDEDSLIE    | IICSRTNQEL | QEINRKYKEM | YKTDLEKDI | SĐTSGDFRK | MVALAKRRRA  |                |    |    |
| EDGSVIDYEL    | IQDARDLYD  | AGVRKGTVD | PKWISIMTER | SVPHLQKVFD | RYKSYPYDM   |                |    |    |
| LESIRKEVGK    | DLENFLNLV  | QCQNKPLYF | ADRLYDSMKG | KGTRDKVLIR | IMVSRSEVDM   |                |    |    |
| LKIRSEFKRK    | YGKSLYYYIQ | QDTKGDYQKA | LLYLCCGGGD |                |                |                |    |    |

Note: Amino terminus and S100-10A binding site.
Abbreviations: S, Serine (AA 26) phosphorylation by PKC; Y, Tyrosine (AA 24) phosphorylation by pp60src.
of the unbound tPA, the ERα−/low and EpCAM−/low cells, MDA-MB-231 and Hs578T, were included as a control. The results showed that the concentration of tPA in the cell culture supernatants of MDA-MB-231 and Hs578T increased significantly due to siRNA-ANXA2 treatment (Figure 5(C)). This is consistent with a previous study, which has assessed tPA after silencing of ANXA2 in MDA-MB-231.33

It is known that ANXA2 has diverse functions, and it is involved in cancer cell motility, invasion, and metastases.34–38 Moreover, the up-regulation of ANXA2 expression in cancer was directly correlated with advanced clinical stage39,40; and higher ANXA2 expression was also observed in metastatic breast and colon cancer cells compared with the non-metastatic cells.36,41 All of these different roles of ANXA2 were linked in different reports to ANXA2-tPA-dependent plasmin generation.20,32,33,42

In conclusion, the current study presents novel findings that may add insights for a better understanding of the complicated roles of EpCAM and ANXA2, which have been investigated and studied separately for decades. These findings include (1) ANXA2 is an interacting partner of EpCAM in the EpCAM− ERα− breast cancer cells; (2) ANXA2 co-localizes with EpCAM at the plasma membrane of EpCAM+ ERα+ breast cancer cells; and (3) This co-localization is of functional significance since EpCAM appeared to support ANXA2 to function as a co-receptor for the tPA, and EpCAM seemed to have a regulatory influence on the expression/sub-cellular localization of ANXA2.

ACKNOWLEDGMENTS

We would like to thank Dr. Åke Engström at the Proteomics Resource Center at the Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden, for processing gel samples for mass spectrometry and protein identification. We would also like to thank the secretariat of higher education in Tripoli, Libya and the Cultural and Student Attachés at the Libyan Embassy in Stockholm for their support of SEG. Also, we would like to thank Najran University, Saudi Arabia and the cultural attaché of Saudi Arabia in Germany for supporting SMA. This work was supported by grants from the Swedish Cancer Society, the Swedish Research Council (VR-M and VR-Linne) and the Cancer Society in Stockholm, Karolinska Institutet and the Stockholm County Council.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

All authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Conceptualization, C.E., M.N.; Methodology, S.M.A.-Q., S.E.G., M.G., D.H.; Investigation, S.M.A.-Q., S.E.G., M.G., C.E.; Formal Analysis, S.M.A.-Q., S.E.G.; Resources, C.E., D.H., M.N.; Writing—Original Draft, S.M.A.-Q., S.E.G., M.G., D.H.; Writing—Review & Editing, D.H., M.N.; Supervision, C.E., D.H., M.N.; Funding Acquisition, M.N.; Data Curation, S.M.A.-Q., S.E.G.; Validation, S.M.A.-Q., M.G.; Project Administration, D.H., M.N.

ETHICAL STATEMENT

Not applicable.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Saad Misher Al-Qahtani https://orcid.org/0000-0002-3871-6747

REFERENCES

1. Chen X, Ma WY, Xu SC, et al. The overexpression of epithelial cell adhesion molecule (EpCAM) in glioma. J Neurooncol. 2014;119:39-47. https://doi.org/10.1007/s11060-014-1459-5
2. Cimino A, Halushka M, Illei P, Wu X, Sukumar S, Argani P. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat. 2010;123(3):701-708. https://doi.org/10.1007/s10549-009-0671-z
3. Goossens-Beumer U, Zeestraaten ECM, Benard A, et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer. 2014;110(12):2935-2944. https://doi.org/10.1038/bjc.2014.226
4. Gostner JM, Fong D, Wurlich OA, et al. Effects of EpCAM over-expression on human breast cancer cell lines. BMC Cancer. 2011;11:1-14. https://doi.org/10.1186/1471-2407-11-45
5. Yang J, Isaji T, Zhang G, et al. EpCAM associates with integrin and regulates cell adhesion in cancer cells. Biochem Biophys Res Commun. 2020;522:903-909. https://doi.org/10.1016/j.bbrc.2019.11.152
6. Gadalla SE, Öjermalm K, Vasquez PL, et al. EpCAM associates with endoplasmic reticulum aminopeptidase 2 (ERAP2) in breast cancer cells. Biochem Biophys Res Commun. 2013;439(2):203-208. https://doi.org/10.1016/j.bbrc.2013.08.059
7. Geisow MJ, Walker JH, Boutstead C, Taylor W. Annexins—new family of Ca2+-regulated phospholipid binding protein. Biosci Rep. 1987;7(4):289-298. https://doi.org/10.1038/BF01121450
8. Martin-Belmonte F, Gassama A, Datta A, et al. PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42. Cell. 2007;128(2):383-397. https://doi.org/10.1016/j.cell.2006.11.051
9. Chutaphisith S, Bean BE, Cowley G, et al. Annexins in human breast cancer: possible predictors of pathological response to neoadjuvant chemotherapy. Eur J Cancer. 2009;45:1274-1281. https://doi.org/10.1016/j.ejca.2008.12.026
10. Liu J, Vishvanatha JK. Regulation of nucleo-cytoplasmic shuttling of human annexin A2—a proposed mechanism. Mol Cell Biochem. 2007;031(1-2):211-220. https://doi.org/10.1007/s11010-007-9477-7
11. Wright JF, Kurosky A, Wasi S. An endothelial cell-surface form of annexin II binds human cytomegalovirus. Biochem Biophys Res Commun. 1994;198:983-989. https://doi.org/10.1016/0006-291X(94)90440-6
12. Goel M, Sienkiewicz AE, Pickin J, Lee RK, Bhattacharya SK. Cochlin induced TREK-1 co-expression and annexin A2 secretion: role in tracheobronchial meshwork cell elongation and motility. PLoS One. 2011;6(8):8-16. https://doi.org/10.1371/journal.pone.0023070
13. Gerke V, Weber K. Identity of p36K phosphorylated upon Rus sarcoma virus transformation with a protein purified from brush borders; calcium-dependent binding to non-erythroid spectrin and F-actin. EMBO J. 1984;3(1):227-233. https://doi.org/10.1002/j.1460-2075.1984.tb01789.x
14. Thiel C, Osborn M, Gerke V. The tight association of the tyrosine kinase substrate annexin II with the submembranous cytoskeleton.
depends on intact p11- and Ca(2+)-binding sites. J Cell Sci. 1992;103(3):733-742.
15. Ali SM, Geisow MJ, Burgoyne RD. A role for calpain in calcium-dependent exocytosis in adrenal chromaffin cells. Nature. 1989;340:313-315. https://doi.org/10.1038/340313a0
16. Creutz CE. The annexins and exocytosis. Science. 1992;258(5084):924-931. https://doi.org/10.1126/science.1439804
17. Jindal HK, Chaney WG, Anderson CW, Davis RG, Vishwanatha JK. The protein-tyrosine kinase substrate, calpain I heavy chain (p36), is part of the primer recognition protein complex that interacts with DNA polymerase α. J Biol Chem. 1991;266(8):5169-5176. https://doi.org/10.1016/s0021-9258(19)67770-7
18. Munz B, Gerke V, Gilitzter R, Werner S. Differential expression of the calpain I subunits annexin II and p11 in cultured keratinocytes and during wound repair. J Invest Dermatol. 1997;108(3):307-312. https://doi.org/10.1111/j.1523-1747.ep12286470
19. Sarafian T, Pradel LA, Henry JP, Aunis D, Bader MF. The participation of annexin II (Calpain I) in calcium-evoked exocytosis requires protein kinase C. J Cell Biol. 1991;114(6):1135-1147. https://doi.org/10.1083/jcb.114.6.1135
20. Bharadwaj A, Bydoun M, Holloway R, Waisman D. Annexin A2 heterotetramer: structure and function. Int J Mol Sci. 2013;14(3):6259-6305. https://doi.org/10.3390/ijms14036259
21. Surette AP, Madureira PA, Phipps KD, Miller VA, Svenningson P, Waisman DM. Regulation of fibrinolysis by S100A10 in vivo. Blood. 2011;118(11):3172-3181. https://doi.org/10.1182/blood-2011-05-353482
22. Ling Q, Jacovina AT, Deora A, et al. Annexin II regulates fibrin homeostasis and neangiogenesis in vivo. J Clin Invest. 2004;113:38-48. https://doi.org/10.1172/JCI19684
23. Parfyonova YV, Piekhanova OS, Tkachuk VA. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Mosc). 2002;67(1):119-134. https://doi.org/10.1023/A:1013964517211
24. Kobiniski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta. 2000;291(1-2):113-135. https://doi.org/10.1016/S0009-8981(99)00224-7
25. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515-527. https://doi.org/10.1016/j.ccr.2006.10.008
26. Gadalla S-E, Alexandraki A, Lindström MS, Nistér M, Ericsson C. Uncoupling of the ERα regulated morphological phenotype from the cancer stem cell phenotype in human breast cancer cell lines. Biochem Biophys Res Commun. 2011;405(4):581-587.
27. Gadalla S-E. Studies of stem cell and adhesion proteins in breast cancer. Inst för Onkologi-Patologi/Dept of Oncology-Pathology; 2014.
28. Pearce ST, Liu J, Jordan VC. Modulation of estrogen receptor α function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem. 2003;278(9):7630-7638. https://doi.org/10.1074/jbc.M211129200
29. Münz M, Zeidler R, Gires O. The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett. 2005;225:151-157. https://doi.org/10.1016/j.canlet.2004.11.048
30. Izumi S, Yamamura S, Hayashi N, Toma M, Tawa K. Dual-color fluorescence imaging of EpCAM and EGFR in breast cancer cells with a bull's eye-type plasmonic chip. Sensors. 2017;17(12):1-7. https://doi.org/10.3390/s17122942
31. Jeon YR, Kim SY, Lee EJ, et al. Identification of annexin II as a novel secretory biomarker for breast cancer. Proteomics. 2013;13:3145-3156. https://doi.org/10.1002/pmic.201300127
32. Diaz VM, Hurtado M, Thomson TM, Reventós J, Paciucci R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004;53(7):993-1000. https://doi.org/10.1136/gut.2003.026831
33. Sharma M, Ownbey RT, Sharma MC. Breast cancer cell surface annexin II induces cell migration and neangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol. 2010;88:278-286. https://doi.org/10.1016/j.yexmp.2010.01.001
34. Zhao P, Zhang W, Tang J, et al. Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147. Cancer Sci. 2010;101(2):387-395. https://doi.org/10.1111/j.1349-7006.2009.01420.x
35. Zhai H, Acharya S, Gravanis I, et al. Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci. 2011;31:14346-14360. https://doi.org/10.1523/JNEUROSCI.3299-11.2011
36. Sharma MR, Kołtowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol. 2006;81:146-156. https://doi.org/10.1016/j.yexmp.2006.03.003
37. Zhang W, Zhao P, Xu XL, et al. Annexin A2 promotes the migration and invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of CD147-harboring microvesicles from tumor cells. PLoS One. 2013;8(8):1-8. https://doi.org/10.1371/journal.pone.0067268
38. Lokman NA, Ween MP, Oehler MK, Ricciardelli C. The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenvir. 2011;4(2):199-208. https://doi.org/10.1002/cnr2.1498
39. Reeves SA, Chavez-Kappel C. Developmental regulation of Annexin II (Lipocortin 2) in human brain and expression in high grade Glioma. Cancer Res. 1992;52(24):6871-6876.
40. Domoto T, Miyama Y, Suzuki H, et al. Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci. 2007;98(1):77-82. https://doi.org/10.1111/j.1349-7006.2006.00355.x
41. Yeatman TJ, Updyke TV, Kaeztel MA, Dedman JR, Nicolson GL. Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells. Clin Exp Metastasis. 1993;11(1):37-44. https://doi.org/10.1007/BF00880064
42. Diaz VM, Planagumà J, Thomson TM, Reventós J, Paciucci R. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology. 2002;122(3):806-819. https://doi.org/10.1053/gast.2002.31885

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Al-Qahtani SM, Gadalla SE, Guo M, Ericsson C, Hägerstrand D, Nistér M. The association between Annexin A2 and epithelial cell adhesion molecule in breast cancer cells. Cancer Reports. 2022;5(5):e1498. https://doi.org/10.1002/cnr2.1498